Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

4.560 +0.080 (+1.79%)

Streaming Delayed Price Updated: 11:21 AM EDT, Mar 25, 2026 Add to My Watchlist

Price and Volume

Volume	19,880
Open	4.480
Bid (Size)	4.550 (300)
Ask (Size)	4.600 (100)
Prev. Close	4.480
Today's Range	4.470 - 4.740
52wk Range	3.280 - 9.821
Shares Outstanding	41,957,197
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm

March 20, 2026

From The Schall Law Firm

Via Business Wire

VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

March 20, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Performance

YTD	-45.1%	-45.1%
1 Month	-18.7%	-18.7%
3 Month	-44.5%	-44.5%
6 Month	+5.8%	+5.8%
1 Year	-12.7%	-12.7%

More News

Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

March 19, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Reports Q4 Earnings Beat and Accelerating Revenue Growth ↗

March 11, 2026

Via Chartmill

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 11, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

March 05, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

February 12, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

February 09, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

January 07, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Which stocks are gapping on Monday? ↗

December 01, 2025

Via Chartmill

Top stock movements in today's session. ↗

November 28, 2025

Via Chartmill

Which stocks are moving on Friday? ↗

November 28, 2025

Via Chartmill

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

November 24, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

November 14, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

November 10, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 24, 2025

From Halper Sadeh LLC

Via Business Wire

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

October 20, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 07, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Top movers in Friday's pre-market session ↗

September 19, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 19, 2025

Via Benzinga

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

September 19, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Posts Profit in Fiscal Q2 ↗

August 12, 2025

Via The Motley Fool

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?

Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?

The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market

What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?

The current price of Verrica Pharmaceuticals Inc. - Common Stock is 4.560

When was Verrica Pharmaceuticals Inc. - Common Stock last traded?

The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 03/25/26 11:21 AM ET

What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?

The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 191.32M

How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?

Verrica Pharmaceuticals Inc. - Common Stock has 191M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.